AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse events. SUZHOU, China, May 29, 2025 /PRNewswire/ -- AccurEdit Therapeutics today...
CRIMSONLOGIC JOINS U.S. CBP'S SECTION 321 DATA PILOT TO DIGITIZE ADVANCE SHIPPER DATA ELEMENTS
This strategic partnership aims to expedite customers clearance and improve risk assessment for low-value shipments. IRVINE, Calif., Dec. 16, 2024 /PRNewswire/ -- Global technology company CrimsonLogic, a wholly-owned subsidiary of PSA...